Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4

1. MASRI, A.
2. SHERRID, M.V.
3. ABRAHAM, T.P.
4. CHOUDHURY, L.
5. GARCIA-PAVIA, P.
6. KRAMER, C.M.
7. BARRIALES-VILLA, R.
8. OWENS, A.T.
9. RADER, F.
10. NAGUEH, S.F.
11. OLIVOTTO, I.
12. SABERI, S.A.R.A.
13. TOWER-RADER, A.
14. WONG, T.C.
15. COATS, C.J.
16. WATKINS, H.U.G.H.
17. FIFER, M.A.
18. SOLOMON, S.D.
19. HEITNER, S.B.
20. JACOBY, D.L.
21. KUPFER, S.
22. MALIK, F.I.
23. MENG, L.I.S.A.
24. SOHN, R.L.
25. WOHLTMAN, A.M.Y.
26. MARON, M.S.
27. Show all authors +

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1016/J.CARDFAIL.2024.02.020 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus